Is Ardelyx, Inc. overvalued or undervalued?

As of 6 November 2019, Ardelyx, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued. Key financial ratios reveal a Price to Book Value of 6.04, an EV to EBIT of -20.67, and an EV to EBITDA of -21.91, indicating significant financial distress and loss-making status. In comparison to its peers, Ardelyx's P/E ratio is not applicable due to losses, while Viking Therapeutics, Inc. has a P/E of -23.15 and ImmunityBio, Inc. has a P/E of -5.55, both reflecting similar challenges. The company's recent stock performance has been poor, with a year-to-date return of -28.40%, significantly underperforming the S&P 500's 2.44% return, further reinforcing the notion of overvaluation amidst its current financial struggles.